Trubion CEO out in management shuffle

Peter Thompson, Trubion Pharmaceuticals' president, CEO, chairman of the board and co-founder, has retired. Steven Gillis, former lead director of Trubion's board, has been appointed executive chairman of the board and acting president. Michelle Burris, Trubion's senior vice president and chief financial officer, will assume the role of chief operating officer, and John Bencich, the company's senior director of finance and accounting, has been promoted to vice president and chief financial officer. Release

Mirna Therapeutics names Paul Lammers as its president and CEO. Release

Cannasat Therapeutics appoints Anthony Giovinazzo to be company CEO. Release

Bruce Galton resigns as Senesco Techonolgies' president and CEO; Jack Van Hulst tapped as his replacement. Release

Steven Paul, executive vice president, science and technology, and president of Lilly Research Laboratories, will retire from Eli Lilly in February; Jan Lundberg, AstraZeneca's executive vice president and head of global discovery research, will succeed him. Release

Watson Pharmaceuticals has announced that Robert Stewart has joined the company in the newly created position of senior VP, global operations, effective immediately. Thomas Russillo, executive VP and president of the generics division, has been named executive VP, global generics. Release

Oxford BioTherapeutics expands U.S. operations, names Jim Cornett chief operating officer and Jon Terrett VP of Oncology. Release

CellCyte Genetics announces the appointment of Douglas Cerretti as chief science officer and director of business development. Release

XOMA has announced that James Neal has joined the company as VP of business development. Release

AnaptysBio has announced the appointment of Sean Stevens as director of cell biology. Release

Cornerstone Therapeutics names Andrew Powell general counsel. Release

Fred Hassan, who headed Schering-Plough until its recent merger with Merck, has been named to Bausch & Lomb's board. Release

Craig Mendelsohn joins Cytomedix's board of directors. Release

Caleco Pharma  appoints Jim Metropoulos to advisory board. Release

Jaye Thompson named to Repros Therapeutics to board of directors. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.